New lens implant helps presbyopia patients ditch reading glasses
NCT ID NCT03499821
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a special lens implant (EVO+ Visian ICL) to improve near vision in 41 adults with presbyopia, an age-related condition that makes it hard to see up close. The lens is placed behind the iris and in front of the eye's natural lens. Six months after surgery, most eyes could see 20/40 or better at 40 cm without glasses. The results suggest this implant may be a helpful option for people who need reading glasses.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- EVO+ Visian ICL with Aspheric (EDOF) Optic (a lens implant)
- What this could lead to
- If successful, this lens could help people with presbyopia see up close without reading glasses.
- What could go wrong
- This is a small, completed study with only 41 participants. Long-term safety and effectiveness are not yet fully known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
41 people
The number who actually took part.
- Started
-
Mar 2018
- Finished
-
Jul 2019
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Must be able to read, understand and provide written informed consent, 2. Willing and able to comply with all treatment and follow-up study related procedures, 3. 40 - 60 years of age at time of surgery if require spherical lens powers from -0.50 D to -18.00 D, 4. 35 - 45 years of age at time of surgery if require a spherical lens power from 0.0 D to +3.00 D, 5. Preoperative refraction fully correctable with available lens powers, with ≤ 0.75 D preoperative refractive and residual cylinder, 6. \< 0.75 D spherical equivalent difference between cycloplegic and manifest refractions, 7. Stable correction (± 0.50 D) as determined by manifest refraction spherical equivalent (MRSE), 8. Best Corrected Distance Visual Acuity 20/20 or better in both eyes, 9. Requires +1.00 D to +2.50 D reading add, 10. Anterior chamber depth (ACD) ≥ 2.8 mm if require spherical lens powers from -0.50 D to -18.00 D, 11. ACD ≥ 3.0 mm if require spherical lens powers from 0.00 D to +3.00 D, 12. Anterior chamber angle ≥ Grade III, 13. Phakic in both eyes, 14. Current contact lens wearers need to demonstrate a stable refraction, (± 0.5 D), expressed as MRSE, on two consecutive examination dates with refractive stability determined by the following criteria: 1. contact lenses were not worn for at least 2 weeks (rigid and toric contact lenses) or 3 days (soft contact lenses) prior to the first refraction, 2. two refractions were performed at least 7 days apart. Exclusion Criteria: 1. Participation in a clinical trial within 30 days prior to entry into this study and/or during the period of study participation, 2. Previous intraocular or corneal surgery in either eye, including refractive surgery, 3. Progressive sight threatening disease or other previous or current ocular conditions, other than myopia in either eye, 4. Low/abnormal corneal endothelial cell density, 5. Amblyopia, 6. Presence of active or history of chronic inflammation in either eye, 7. Clinically significant irregular astigmatism in either eye, 8. Serious, acute, chronic or systemic, non-ophthalmic disease or illness that would increase the operative risk, confound the outcome(s) of the study or which may preclude study completion, 9. Use of topical steroids at time of implantation, 10. Systemic or topical medication, other than prescribed study medications that may confound the outcome or increase the risk to the subject, 11. Allergy to anesthetics or other postoperative medications required in this study, 12. Subject who is pregnant, plans to become pregnant, or is lactating during the course of the study, or has another condition associated with the fluctuation of hormones that could lead to refractive changes, 13. Subjects who present any emotional, physiologic, or anatomical condition which may preclude study participation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Presbyopia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clínica Oftalmológica Gasteiz
Vitoria-Gasteiz, 01005, Spain
-
IMO Instituto de Microcirugía Ocular
Barcelona, 08035, Spain
-
Innova Ocular Begitek
San Sebastián, 20012, Spain
-
Instituto Oftalmológico Fernández-Vega
Oviedo, Principality of Asturias, 33012, Spain
-
Mediopolis
Antwerp, B-2610, Belgium
-
Qvision-Hospital Vithas Virgen del Mar
Almería, 04120, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A lens that could let cataract patients see near and far without glasses
- Eye scans as a window to the body: study probes retinal imaging across diseases
- Can newer cataract lenses keep vision clear for years?
- Which multifocal lens delivers sharper sight? a Head-to-Head test
- A simple fix: could reading glasses boost factory output?
- A simple pair of glasses could keep thousands of workers employed